1. Maria is managing a project for developing a new drug for COVID-19. As part of performance quantitative risk analysis, Maria and her project team completed the sensitivity analysis, created decision trees, and completed a project simulation using the Monte Carlo technique. When she presented the results to the project sponsor, the sponsor is not happy with the results. The sponsor thinks that the results are not accurate because: Which option is right? A. Monte Carlo simulations are not a standard methodology used in the company. B. The quantitative values of identified risks are too high. C. She has not involved the project stakeholders and subject matter experts in the process. D. She has not created a probability impact risk rating matrix as part of the project